These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 19024623)

  • 21. Are there unintended consequences of step-therapy programs?
    Cox ER; Seiz BJ
    Am J Manag Care; 2009 Sep; 15(9):654, 656; author reply 656. PubMed ID: 19747030
    [No Abstract]   [Full Text] [Related]  

  • 22. Public health value of fixed-dose combinations in hypertension.
    Ruilope LM; Burnier M; Muszbek N; Brown RE; Keskinaslan A; Ferber P; Harms G
    Blood Press Suppl; 2008 Jun; 1():5-14. PubMed ID: 18705530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NIH promotes use of lower cost drugs for hypertension.
    Spurgeon D
    BMJ; 2004 Mar; 328(7439):539. PubMed ID: 15001483
    [No Abstract]   [Full Text] [Related]  

  • 24. Relative costs of antihypertensive drug treatment.
    Strasser T
    J Hum Hypertens; 1992 Dec; 6(6):489-94. PubMed ID: 1296015
    [No Abstract]   [Full Text] [Related]  

  • 25. [Medical economics of antihypertensive agents].
    Yamazaki T
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():285-8. PubMed ID: 16981557
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost considerations in the drug treatment of hypertension. Is older better?
    Kaplan NM
    Pharmacoeconomics; 1996 Apr; 9(4):283-5. PubMed ID: 10160102
    [No Abstract]   [Full Text] [Related]  

  • 27. [Discontinuation of subsidizing of certain antihypertensive agents is not well thought-out].
    Berggren B; Lindström T; Nyström F; Cizinsky S; Weiss L; Willenheimer R
    Lakartidningen; 2008 Aug 27-Sep 2; 105(35):2345-6. PubMed ID: 18831442
    [No Abstract]   [Full Text] [Related]  

  • 28. The cost of treating high blood pressure in general practice in France.
    Tibi-Levy Y; de Pouvourville G; Westerloppe J; Bamberger M
    Eur J Health Econ; 2008 Aug; 9(3):229-36. PubMed ID: 17566802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Out-of-pocket costs to users: medicine options for hypertension.
    Arredondo A
    Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pharmacoeconomic aspects of the treatment of essential hypertension].
    Martynov AI; Giliarevskiĭ SR; Ostroumova OD; Nesterova MV; Mamaev VI
    Ter Arkh; 2001; 73(9):82-8. PubMed ID: 11642090
    [No Abstract]   [Full Text] [Related]  

  • 31. Blood-pressure-related disease is a global health priority.
    Macmahon S; Alderman MH; Lindholm LH; Liu L; Sanchez RA; Seedat YK
    J Hypertens; 2008 Oct; 26(10):2071-2. PubMed ID: 18806633
    [No Abstract]   [Full Text] [Related]  

  • 32. Community attributable risk: its economic dimensions.
    Wilhelmsen L
    J Hum Hypertens; 1992 Dec; 6(6):469-72. PubMed ID: 1296011
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic.
    Caro JJ; Lee K
    Curr Hypertens Rep; 2002 Dec; 4(6):418. PubMed ID: 12419167
    [No Abstract]   [Full Text] [Related]  

  • 34. [Antihypertensive treatment. Benefits and costs].
    Jensen HA; Svendsen TL
    Ugeskr Laeger; 1993 Jan; 155(2):118-20. PubMed ID: 8421861
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost effective analyses in the treatment of high blood pressure.
    Fletcher A
    J Hum Hypertens; 1992 Dec; 6(6):437-45. PubMed ID: 1296007
    [No Abstract]   [Full Text] [Related]  

  • 36. [Investigation and treatment of primary hypertension].
    Lindstedt I; Nilsson PM
    Lakartidningen; 2008 Jul 23-Aug 5; 105(30-31):2107-12. PubMed ID: 18751450
    [No Abstract]   [Full Text] [Related]  

  • 37. [Decisions by the state, county council's money and my patient. Consequences of the LFN survey of antihypertensive agents].
    André M; Andersén-Karlsson E; Landahl S; Löfmark R; Silfverhielm B; Skoglund I
    Lakartidningen; 2008 May 21-27; 105(21):1549-50. PubMed ID: 18574990
    [No Abstract]   [Full Text] [Related]  

  • 38. [The comparative assessment of the efficacy of hypotensive preparations in stage-II hypertension].
    Tiurin VP; Fursov AN; Gospodarenko AL; Liapkova NB; Orlov FA
    Voen Med Zh; 1997 Nov; 318(11):46-7. PubMed ID: 9461836
    [No Abstract]   [Full Text] [Related]  

  • 39. The treatment of hypertension in Canada: are we making progress?
    McAlister FA
    CMAJ; 1999 Sep; 161(6):713-4. PubMed ID: 10513278
    [No Abstract]   [Full Text] [Related]  

  • 40. Considerations in the treatment of mild-to-moderate hypertension.
    Giaquinta D
    Manag Care Interface; 2001 Mar; 14(3):80-1. PubMed ID: 11301960
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.